InvestLog
HRMY Harmony Biosciences Holdings, Inc. logo

HRMY Harmony Biosciences Holdings, Inc.

Healthcare
$30.15-1.12%ClosedMarket Cap: $1.75B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

10.53

PEG

1.16

P/B

1.91

P/S

1.94

EV/EBITDA

5.84

DCF Value

$116.24

FCF Yield

19.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

76.5%

Operating Margin

21.1%

Net Margin

16.2%

ROE

17.2%

ROA

11.4%

ROIC

12.5%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$215.4M$32.5M$—
Q4 null$243.8M$22.5M$—
FY null$868.5M$158.7M$—
Q3 null$239.5M$50.9M$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$43.00

Target (Median)

$45.50

Target Range

$31.00 - $50.00

2 Strong Buy4 Buy4 Hold0 Sell1 Strong Sell
Truist SecuritiesHold
2026-05-08
NeedhamBuy
2026-02-25
UBSNeutral
2026-02-25
HC Wainwright & Co.Buy
2026-02-25
B of A SecuritiesUnderperform
2026-02-25

Trading Activity

Insider Trades

View All
Szyper Linda Mdirector
SellMon May 18
Sender Garydirector
SellMon May 18
Sabater Juan A.director
SellMon May 18
Philip Ron Mdirector
SellMon May 18
Graf R. Markdirector
SellMon May 18

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

0.96

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Peers

ABCL logoABCLAUPH logoAUPHBHVN logoBHVNCLDX logoCLDXIMCR logoIMCRJANX logoJANXMNKD logoMNKDNUVB logoNUVBSION logoSIONVERA logoVERA